doxorubicin hydrochloride liposome

liposomal doxorubicin hydrochloride

A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects; a liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1555" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1555" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000039424

liposomal doxorubicin hydrochloride

doxorubicin HCl liposome

pegylated liposomal doxorubicin hydrochloride

Pegylated Liposomal Doxorubicin

liposomal doxorubicin

TLC D-99

Stealth Liposomal Doxorubicin

Doxorubicin Hydrochloride Liposomal

(8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride

duomeisu

doxorubicin hydrochloride liposome injection

ATI-0918

Pegylated Liposomal Doxorubicin Hydrochloride

liposome-encapsulated doxorubicin

liposomal adriamycin

Doxilen

S-Liposomal Doxorubicin

Caelyx

pegylated doxorubicin HCl liposome

Doxil

http://purl.bioontology.org/ontology/PDQ/CDR0000037782

http://purl.bioontology.org/ontology/PDQ/CDR0000038301

http://purl.bioontology.org/ontology/PDQ/CDR0000258432

http://purl.bioontology.org/ontology/PDQ/CDR0000038232

http://purl.bioontology.org/ontology/PDQ/CDR0000042954

http://purl.bioontology.org/ontology/PDQ/CDR0000415354

http://purl.bioontology.org/ontology/PDQ/CDR0000037855

http://purl.bioontology.org/ontology/PDQ/CDR0000043066

http://purl.bioontology.org/ontology/PDQ/CDR0000438802

http://purl.bioontology.org/ontology/PDQ/CDR0000355720

http://purl.bioontology.org/ontology/PDQ/CDR0000043099

http://purl.bioontology.org/ontology/PDQ/CDR0000043078

http://purl.bioontology.org/ontology/PDQ/CDR0000038044

http://purl.bioontology.org/ontology/PDQ/CDR0000043062

http://purl.bioontology.org/ontology/PDQ/CDR0000042780

http://purl.bioontology.org/ontology/PDQ/CDR0000269351

http://purl.bioontology.org/ontology/PDQ/CDR0000038094

http://purl.bioontology.org/ontology/PDQ/CDR0000043088

http://purl.bioontology.org/ontology/PDQ/CDR0000371732

http://purl.bioontology.org/ontology/PDQ/CDR0000441230

http://purl.bioontology.org/ontology/PDQ/CDR0000038539

http://purl.bioontology.org/ontology/PDQ/CDR0000043110

http://purl.bioontology.org/ontology/PDQ/CDR0000037876

http://purl.bioontology.org/ontology/PDQ/CDR0000393828

http://purl.bioontology.org/ontology/PDQ/CDR0000038023

C4287784

C1512061

C0701183

C0717726

C0701184

C1522690

C1522689

C4287823

C0279284

C1704361

2018-06-05

A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects; a liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1555" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1555" NCI Thesaurus)

31919

2059

TRD

C1555

CDR0000039424

712227

Drug/agent

doxorubicin hydrochloride liposome

T109

T195

T200

T121